Details about Margaret K. Kyle

Access statistics for papers by Margaret K. Kyle.

Last updated 2025-05-16. Update your information in the RePEc Author Service.

Short-id: pky20

Working Papers

2024

1. Hot tub time machine? What role for Towercast in EU merger control
   Post-Print, HAL

2023

2. The economics of new product launches and access to pharmaceutical products in the EU: A perspective on the EC’s proposed reform of the EU pharmaceutical legislation
   Post-Print, HAL

2022

3. COVID-19 and clinical trials
   Post-Print, HAL
4. Economic Issues in Assessing Potential and Nascent Competition
   Post-Print, HAL
5. Incentives for pharmaceutical innovation: What’s working, what’s lacking
   Post-Print, HAL
   See also Journal Article Incentives for pharmaceutical innovation: What’s working, what’s lacking, International Journal of Industrial Organization, Elsevier (2022) (2022)
6. Intersection of Intellectual Property and Competition Policy in Recent Cases
   Post-Print, HAL

2021

7. Do Patents Work? Evidence from Pharmaceutical Innovation
   Post-Print, HAL
8. Innovation pharmaceutique: comment combler le retard français ?
   Post-Print, HAL

2020

9. The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals
   Post-Print, HAL View citations (2)
   Also in Post-Print, HAL (2019)
   See also Chapter The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals, NBER Chapters, National Bureau of Economic Research, Inc (2019) (2019)
   Journal Article The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals, Innovation Policy and the Economy, University of Chicago Press (2020) View citations (2) (2020)

2019

10. Productivity and competitiveness in the euro area: A view from France
    (Productivité et compétitivité: où en est la France dans la zone euro ?)
    SciencePo Working papers Main, HAL
    Also in Post-Print, HAL (2019) View citations (1)
11. The More We Die, The More We Sell? A Simple Test of the Home-Market Effect*
    Post-Print, HAL View citations (6)
    Also in Working Papers, HAL (2016) View citations (15)
    NBER Working Papers, National Bureau of Economic Research, Inc (2016) View citations (14)
    See also Journal Article The More We Die, The More We Sell? A Simple Test of the Home-Market Effect, The Quarterly Journal of Economics, President and Fellows of Harvard College (2019) View citations (38) (2019)
12. The Single Market in Pharmaceuticals
    Post-Print, HAL
    See also Journal Article The Single Market in Pharmaceuticals, Review of Industrial Organization, Springer (2019) View citations (2) (2019)

2018

13. Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets
    Post-Print, HAL View citations (3)
    Also in CEPR Discussion Papers, C.E.P.R. Discussion Papers (2017)
    Working Papers, HAL (2017)
    Working Papers, HAL (2016)
    See also Journal Article Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets, Review of Industrial Organization, Springer (2018) View citations (4) (2018)

2017

14. Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs
    Post-Print, HAL View citations (4)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (2017) View citations (5)
    Post-Print, HAL (2016) View citations (2)
    See also Journal Article Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs, American Economic Review, American Economic Association (2017) View citations (5) (2017)
15. Korean pharmaceutical industry policy: lessons for Korea
    Working Papers, HAL
16. Strategic Interaction Among Governments in the Provision of a Global Public Good
    CEPR Discussion Papers, C.E.P.R. Discussion Papers View citations (7)
    Also in Post-Print, HAL (2017) View citations (7)
    Post-Print, HAL (2017) View citations (7)
    See also Journal Article Strategic interaction among governments in the provision of a global public good, Journal of Public Economics, Elsevier (2017) View citations (7) (2017)

2016

17. Competition Law, Intellectual Property, and the Pharmaceutical Sector
    Post-Print, HAL View citations (7)
    Also in Post-Print, HAL (2016) View citations (7)
18. Competition and the Efficiency of Markets for Technology
    Post-Print, HAL View citations (11)
    Also in SciencePo Working papers Main, HAL (2016) View citations (2)
    IDEI Working Papers, Institut d'Économie Industrielle (IDEI), Toulouse (2013) View citations (6)
    TSE Working Papers, Toulouse School of Economics (TSE) (2013) View citations (2)
    See also Journal Article Competition and the Efficiency of Markets for Technology, Management Science, INFORMS (2016) View citations (15) (2016)
19. Estimating the Benefits of Cancer Treatments
    Post-Print, HAL
20. Estimating the Benefits of Innovation
    Working Papers, HAL
21. Government Free-riding in Research Funding
    Working Papers, HAL
22. Intellectual Property Rights and Access to Innovation: Evidence from TRIPS
    Working Papers, HAL
    Also in Working Papers, HAL (2014) View citations (14)
    NBER Working Papers, National Bureau of Economic Research, Inc (2014) View citations (19)
23. Study for European Commission (DG Internal Market, Industry, Entrepreneurship and SMEs) on supplementary patent certificates
    Post-Print, HAL
24. The Effects of Pharmaceutical Innovation on Cancer Mortality
    CEPR Discussion Papers, C.E.P.R. Discussion Papers View citations (1)
25. The Effects of Pharmaceutical Innovation on Cancer Mortality Rates
    TSE Working Papers, Toulouse School of Economics (TSE) View citations (1)

2012

26. Assessing the population health impact of market interventions to improve access to antiretroviral treatment
    Post-Print, HAL
27. Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration
    Post-Print, HAL

2011

28. Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act
    Post-Print, HAL View citations (1)
29. Inefficiencies in technology transfer: theory and empirics
    CEPR Discussion Papers, C.E.P.R. Discussion Papers View citations (7)
    Also in SciencePo Working papers Main, HAL (2011)
    Working Papers, HAL (2011) View citations (5)
30. Inefficiencies in the sale of ideas: theory and empirics
    Working Papers, HAL View citations (1)
    Also in SciencePo Working papers Main, HAL (2011)
31. Investments in Pharmaceuticals Before and After TRIPS
    CEPR Discussion Papers, C.E.P.R. Discussion Papers View citations (4)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (2009) View citations (10)
    See also Journal Article Investments in Pharmaceuticals Before and After TRIPS, The Review of Economics and Statistics, MIT Press (2012) View citations (73) (2012)

2007

32. Strategic Responses to Parallel Trade
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (17)
    See also Journal Article Strategic Responses to Parallel Trade, The B.E. Journal of Economic Analysis & Policy, De Gruyter (2011) View citations (36) (2011)

2006

33. Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (37)
    See also Journal Article Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research, Annals of Economics and Statistics, GENES (2005) View citations (22) (2005)

2000

34. Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did They Get Easier During the Banking Boom? Did It Matter to Bank Lending?
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (16)
    Also in Finance and Economics Discussion Series, Board of Governors of the Federal Reserve System (U.S.) (2000) View citations (2)
    See also Chapter Did US Bank Supervisors Get Tougher during the Credit Crunch? Did They Get Easier during the Banking Boom? Did It Matter to Bank Lending?, NBER Chapters, National Bureau of Economic Research, Inc (2001) View citations (33) (2001)

Journal Articles

2025

1. Lessons for the United States from Pharmaceutical Regulation Abroad
   Journal of Economic Perspectives, 2025, 39, (2), 53-78

2022

2. Incentives for pharmaceutical innovation: What’s working, what’s lacking
   International Journal of Industrial Organization, 2022, 84, (C)
   See also Working Paper Incentives for pharmaceutical innovation: What’s working, what’s lacking, Post-Print (2022) (2022)

2020

3. The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals
   Innovation Policy and the Economy, 2020, 20, (1), 95 - 123 View citations (2)
   See also Chapter The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals, NBER Chapters, 2019, 95-123 (2019) (2019)
   Working Paper The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals, Post-Print (2020) View citations (2) (2020)

2019

4. The More We Die, The More We Sell? A Simple Test of the Home-Market Effect
   The Quarterly Journal of Economics, 2019, 134, (2), 843-894 View citations (38)
   See also Working Paper The More We Die, The More We Sell? A Simple Test of the Home-Market Effect*, Post-Print (2019) View citations (6) (2019)
5. The Single Market in Pharmaceuticals
   Review of Industrial Organization, 2019, 55, (1), 111-135 View citations (2)
   See also Working Paper The Single Market in Pharmaceuticals, Post-Print (2019) (2019)

2018

6. Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets
   Review of Industrial Organization, 2018, 53, (1), 211-234 View citations (4)
   See also Working Paper Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets, Post-Print (2018) View citations (3) (2018)

2017

7. Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs
   American Economic Review, 2017, 107, (5), 486-90 View citations (5)
   See also Working Paper Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs, Post-Print (2017) View citations (4) (2017)
8. Strategic interaction among governments in the provision of a global public good
   Journal of Public Economics, 2017, 156, (C), 185-199 View citations (7)
   See also Working Paper Strategic Interaction Among Governments in the Provision of a Global Public Good, CEPR Discussion Papers (2017) View citations (7) (2017)

2016

9. Competition and the Efficiency of Markets for Technology
   Management Science, 2016, 62, (4), 1000-1019 View citations (15)
   See also Working Paper Competition and the Efficiency of Markets for Technology, Post-Print (2016) View citations (11) (2016)

2013

10. Intellectual Property Protection and the Geography of Trade
    Journal of Industrial Economics, 2013, 61, (3), 733-762 View citations (53)

2012

11. Investments in Pharmaceuticals Before and After TRIPS
    The Review of Economics and Statistics, 2012, 94, (4), 1157-1172 View citations (73)
    See also Working Paper Investments in Pharmaceuticals Before and After TRIPS, CEPR Discussion Papers (2011) View citations (4) (2011)

2011

12. Strategic Responses to Parallel Trade
    The B.E. Journal of Economic Analysis & Policy, 2011, 11, (2), 34 View citations (36)
    See also Working Paper Strategic Responses to Parallel Trade, NBER Working Papers (2007) View citations (17) (2007)

2007

13. Generic competition and market exclusivity periods in pharmaceuticals
    Managerial and Decision Economics, 2007, 28, (4-5), 491-502 View citations (54)
14. Pharmaceutical Price Controls and Entry Strategies
    The Review of Economics and Statistics, 2007, 89, (1), 88-99 View citations (149)

2006

15. Objective and self‐report work performance measures: a comparative analysis
    International Journal of Productivity and Performance Management, 2006, 55, (5), 390-399
16. The role of firm characteristics in pharmaceutical product launches
    RAND Journal of Economics, 2006, 37, (3), 602-618 View citations (47)

2005

17. Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research
    Annals of Economics and Statistics, 2005, (79-80), 165-188 View citations (22)
    See also Working Paper Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research, NBER Working Papers (2006) View citations (37) (2006)

2004

18. Does locale affect R&D productivity? the case of pharmaceuticals
    FRBSF Economic Letter, 2004, (nov12)

2002

19. Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales
    Journal of Law and Economics, 2002, 45, (S2), 691-723 View citations (35)

Chapters

2019

1. The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals
   A chapter in Innovation Policy and the Economy, Volume 20, 2019, pp 95-123
   See also Working Paper The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals, HAL (2020) View citations (2) (2020)
   Journal Article The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals, University of Chicago Press (2020) View citations (2) (2020)

2011

2. Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions
   Elsevier

2010

3. Public and Private Spillovers: Location and the Productivity of Pharmaceutical Research
   A chapter in Contributions in Memory of Zvi Griliches, 2010, pp 165-188 View citations (17)

2008

4. Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity
   Chapter 11 in The Economics of Corporate Governance and Mergers, 2008 View citations (3)

2003

5. The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches
   A chapter in Scanner Data and Price Indexes, 2003, pp 229-267 View citations (30)

2001

6. Did US Bank Supervisors Get Tougher during the Credit Crunch? Did They Get Easier during the Banking Boom? Did It Matter to Bank Lending?
   A chapter in Prudential Supervision: What Works and What Doesn't, 2001, pp 301-356 View citations (33)
   See also Working Paper Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did They Get Easier During the Banking Boom? Did It Matter to Bank Lending?, National Bureau of Economic Research, Inc (2000) View citations (16) (2000)

Software Items

1997

1. MATLAB/C code for GIG and BNLG common value auction specifications
   Matlab codes